Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2105
https://www.valueinhealthjournal.com/article/S1098-3015(15)04181-9/fulltext
Title :
Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04181-9&doi=10.1016/j.jval.2015.09.2105
First page :
A609
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1522